This brief was filed on behalf of leading medical and public health societies representing physicians, clinicians, and public health professionals who serve patients in Texas and nationwide, whose ability to effectively care for patients often requires access to mifepristone, which has undergone rigorous testing and review and has been approved for use in the United States for over 20 years.

The brief emphasizes that mifepristone has been studied and is conclusively safe, that REMS restrictions are not necessary to ensure patient safety, and that enjoining the use of mifepristone will harm pregnant patients and have severe negative impacts on the broader health care system.

This brief was one of many filed in Alliance for Hippocratic Medicine v. FDA. For more information on the case, click here.